Lila Levinson

3 weeks ago | multiplesclerosisnewstoday.com | Lila Levinson

The PoNS device has shown significant benefits in walking and balance in clinical trials, and benefits were seen in real-world studies.

1 month ago | alsnewstoday.com | Lila Levinson |Lindsey Shapiro |Patricia Inacio |Marta C. Figueiredo

Daily treatment with IPL344 for up to three years was safe and appeared to slow amyotrophic lateral sclerosis (ALS) progression, according to recently published data from a small Phase 2a clinical trial. Patients undergoing treatment gained weight and experienced slower declines in functional abilities and lung function. The treatment also lengthened survival in patients, compared with external placebo groups.